SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Quick Stats
Jan 30, 202655.2
AI Score
HOLD0.47
Volume Ratio
Mar 19, 2026
Next Earnings
17
+ve Days (30d)
13
-ve Days (30d)
SLS Stock Summary
Last updated Jan 30, 2026
SLS is currently trading at $3.77, positioned above its 200-day moving average of $2.03, indicating a long-term uptrend. The stock has a 52-week range of $0.9516 to $5.1765.
Technical Analysis: The 50-day moving average stands at $2.91, which is below the current price, signaling bullish near-term momentum. The RSI (Relative Strength Index) reads 50.622, suggesting the stock is neutral with balanced momentum.
Money Flow Indicators: The Chaikin Money Flow (20-day) is 0.133, which is positive, indicating accumulation by institutional investors. Our AI-powered investment score rates SLS at 55.2/100 with a HOLD recommendation.
SLS (SELLAS Life Sciences Group, Inc. Common Stock) Indicators
Last updated Jan 30, 2026
| Indicator | Value |
|---|---|
| RSI(14) | 50.622 |
| CMF (20) | 0.133 |
| ROC (10) | -1.823 |
| ADX (14) | 42.08 |
| Indicator | Value |
|---|---|
| MACD (12,26,9) | 0.296 |
| AROONOSC (14) | 57.143 |
| WILLAMS %R (14) | -71.333 |
| MFI (14) | 68.042 |
SLS Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select indicators above to analyze technical patterns
Indicators will appear below the price chart with perfectly aligned datesVolume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
SLS Price vs Max Options Open Interest
SLS Max Change In Options Open Interest
SLS Options - Sort by Max open Interest (near term)
30th January 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
SLS Daily Out of Money Options - Sort by Max open Interest (near term)
30th January 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
SLS Daily In the Money Options - Sort by Max open Interest (near term)
30th January 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
SLS Most Active Options by Volume(near term)
30th January 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
SELLAS Life Sciences Group, Inc. Common Stock is above both 50 Day and 200 Day SMA which is considered Bullish.
SLS Moving Averages Analysis
SELLAS Life Sciences Group, Inc. Common Stock has been above 50 day sma 1 times in last 30 days. Last time it was above 50 day sma was on Jan 30, 2026
SELLAS Life Sciences Group, Inc. Common Stock has been above 200 day sma 1 times in last 30 days. Last time it was above 200 day sma was on Jan 30, 2026
SLS (SELLAS Life Sciences Group, Inc. Common Stock) Simple Moving Averages
Moving Averages are last updated Jan 30, 2026
| Days | MA |
|---|---|
| 10 | 4.2 |
| 20 | 4.15 |
| 30 | 3.71 |
| 50 | 2.91 |
| 100 | 2.34 |
| 200 | 2.03 |
SLS Fundamental Analysis
| P/E (Forward) | 0 |
| P/E (Trailing) | -- |
| Market Cap ($) | 675.2 million |
| Earnings/Share ($) | -0.28 |
| Net Proft Margin (%) | 0 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | -0.26 |
| EPS Estimate Next Year ($) | -0.3167 |
| WallStreet Target Price ($) | 6.8333 |
| Most Recent Quarter |
News Summary: Investors speculate on the future of Sellas Life Sciences Group, Inc. ($SLS) as CEO Dr. Angelos Stergiou makes bold statements hinting at positive outcomes for the GPS Regal Pivotal Registrational Phase 3 study in AML CR2/CRp2. The stock is seen as a solid buy at current prices, with institutional holders holding strong. Speculation arises about a potential halt in trading, causing concern for short sellers.
Updated 2026-01-30 21:00:02